Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KIF5B | P33176 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221520 | 0.84 | MTNR1B (0.44) | TTRPOLBKDRSLC6A2SLC6A4 | |
| SCHEMBL4244015 | 0.80 | SIRT2 (0.48) | POLBSMN1; SMN2RETKIF5BKDR | |
| SCHEMBL7228045 | 0.79 | ALOX5 (0.47) | TTRF2LTA4H | |
| SCHEMBL29215397 | 0.76 | GABRA1 (0.49) | TTRAPPF2LTA4HGPBAR1 | |
| SCHEMBL30979261 | 0.76 | GABRA1 (0.49) | TTRAPPF2LTA4HGPBAR1 | |
| SCHEMBL13871440 | 0.75 | GAA (0.46) | THRBESR1ESR2KDRSLC6A2 | |
| SCHEMBL12711141 | 0.75 | KDM4E (0.42) | TTR | |
| SCHEMBL23530077 | 0.73 | S1PR1 (0.42) | TSHR | |
| SCHEMBL13871447 | 0.72 | CYP1A2 (0.46) | TTRTHRATHRBESR1ESR2 | |
| SCHEMBL6667570 | 0.72 | LTA4H (0.56) | TTRPOLBRHEBLTA4HSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6573278-B2 | For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| EP-0966436-B1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BAYER AG (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-20020072529-A1 | Arylsulfonamides and analogues | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6262112-B1 | 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| EP-0966436-A1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Bayer Aktiengesellschaft (DE) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998037061-A1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072529-A1 | Arylsulfonamides and analogues | ARSA, PRSS12, SNCA | TTR 131/4885APP 30/4885F2 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.